Correction to: Scientific Reports 10.1038/s41598-020-69610-x, puplished online 28 July 2020
This Article contains an error in Figure 6 where the PERK inhibitor ‘GSK2606414’ is incorrectly referred to as ‘GSK2656157’. As a result, the Figure legend,
“A model of the effect of the CSE-induced ER stress on efferocytosis. ER stress and oxidative stress induced by smoking activate the PERK-eIF2α pathway. The results of the experiments using TUDCA, GSK2656157 and salubrinal highlight the therapeutic potential of TUDCA in the impairment of efferocytosis by cigarette smoke.”
should read:
“A model of the effect of the CSE-induced ER stress on efferocytosis. ER stress and oxidative stress induced by smoking activate the PERK-eIF2α pathway. The results of the experiments using TUDCA, GSK2606414 and salubrinal highlight the therapeutic potential of TUDCA in the impairment of efferocytosis by cigarette smoke.”
The correct Figure 6 appears below as Figure 1.
Figure 1.
A model of the effect of the CSE-induced ER stress on efferocytosis. ER stress and oxidative stress induced by smoking activate the PERK-eIF2α pathway. The results of the experiments using TUDCA, GSK2606414 and salubrinal highlight the therapeutic potential of TUDCA in the impairment of efferocytosis by cigarette smoke.